TACR1 and neoplasm: This representative of NK1R antagonists is of increasing attentiveness due to its broad anti-tumor activity of very promising therapeutic significance [12,13,19,20] and many years of experience in clinical application against chemotherapy-induced nausea and vomiting in oncological patients.